A61K 47/6801
Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
Official title: {Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}
A61K47/6801 (Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent) appears on 4,022 US grants and 7,598 published applications in this corpus.
Search patents in A61K- Granted patents
- 4,022
- Published applications
- 7,598
- Assignees
- 1,909
- Inventors
- 11,227
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 2 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 7 | 0 |
| 1983 | 6 | 0 |
| 1984 | 4 | 0 |
| 1985 | 2 | 0 |
| 1986 | 4 | 0 |
| 1987 | 11 | 0 |
| 1988 | 12 | 0 |
| 1989 | 13 | 0 |
| 1990 | 22 | 0 |
| 1991 | 13 | 0 |
| 1992 | 24 | 0 |
| 1993 | 17 | 0 |
| 1994 | 12 | 0 |
| 1995 | 12 | 0 |
| 1996 | 17 | 0 |
| 1997 | 35 | 0 |
| 1998 | 60 | 0 |
| 1999 | 39 | 0 |
| 2000 | 37 | 0 |
| 2001 | 27 | 7 |
| 2002 | 36 | 43 |
| 2003 | 30 | 83 |
| 2004 | 25 | 79 |
| 2005 | 20 | 91 |
| 2006 | 35 | 93 |
| 2007 | 29 | 79 |
| 2008 | 32 | 92 |
| 2009 | 61 | 129 |
| 2010 | 66 | 118 |
| 2011 | 51 | 144 |
| 2012 | 84 | 143 |
| 2013 | 94 | 163 |
| 2014 | 116 | 245 |
| 2015 | 127 | 280 |
| 2016 | 192 | 406 |
| 2017 | 216 | 399 |
| 2018 | 226 | 456 |
| 2019 | 289 | 471 |
| 2020 | 281 | 457 |
| 2021 | 297 | 512 |
| 2022 | 259 | 529 |
| 2023 | 293 | 649 |
| 2024 | 287 | 683 |
| 2025 | 300 | 702 |
| 2026 | 196 | 545 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy6 Oct 2026US 12,752,013 B2Dyne Therapeutics, Inc.
- Disruption of CD28-sialoside ligand complexes to enhance T cell activation6 Oct 2026US 12,752,014 B2The Scripps Research Institute
- Anti-Nectin-4 antibody, conjugate including the same, and application thereof6 Oct 2026US 12,753,230 B2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Antibody conjugates and uses thereof6 Oct 2026US 12,753,242 B2GlycoNex Inc.
- Camptothecin derivatives29 Sep 2026US 12,747,250 B2ImmunoGen, Inc.
- Prefusion-stabilized human parainfluenza virus 3 f proteins8 Oct 2026US 2026/0306613 A1Board of Regents, The University of Texas System
- Asgpr binders and compositions and methods thereof8 Oct 2026US 2026/0306647 A1Biohaven Therapeutics Ltd.
- Delivery of dual payload of mmaf or mmae and tlr7 agonists8 Oct 2026US 2026/0306648 A1The Research Foundation for The State University of New York
- Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab8 Oct 2026US 2026/0306649 A1Agensys, Inc.
- Camptothecin drug conjugate and use thereof8 Oct 2026US 2026/0306650 A1Shanghai Zaimo Biotechnology Co., Ltd.
Most cited
By later US patents
- Cytotoxic agents comprising maytansinoids and their therapeutic use805US 5,208,020 AImmunoGen, Inc. · 1993
- Lysosomal enzyme-cleavable antitumor drug conjugates653US 6,214,345 B1Bristol-Myers Squibb Company · 2001
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Therapeutic inhibitor of vascular smooth muscle cells562US 5,733,925 ANeoRx Corporation · 1998
- Solubilization of proteins for pharmaceutical compositions using polymer conjugation538US 4,766,106 ACetus Corporation · 1988